{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:57:02Z","timestamp":1768431422829,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.micpath.2024.106821","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T02:01:18Z","timestamp":1722304878000},"page":"106821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Investigating the role of GTPase in inhibiting HBV replication and enhancing interferon therapy efficacy in chronic hepatitis B patients"],"prefix":"10.1016","volume":"194","author":[{"given":"Dongmei","family":"Quan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2024.106821_bib1","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01557-22","article-title":"IFIT3 is increased in serum from patients with chronic hepatitis B virus (HBV) infection and promotes the anti-HBV effect of interferon alpha via JAK-STAT2 in vitro","volume":"10","author":"Xu","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"2","key":"10.1016\/j.micpath.2024.106821_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.micpath.2024.106821_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.766534","article-title":"In vivo mouse models for hepatitis B virus infection and their application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.micpath.2024.106821_bib5","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1136\/gutjnl-2019-319637","article-title":"Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription","volume":"69","author":"Salerno","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.micpath.2024.106821_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.tim.2018.01.009","article-title":"Hepatitis B virus","volume":"26","author":"Shih","year":"2018","journal-title":"Trends Microbiol."},{"issue":"28","key":"10.1016\/j.micpath.2024.106821_bib7","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.3748\/wjg.v21.i28.8653","article-title":"Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients","volume":"21","author":"Ge","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.micpath.2024.106821_bib8","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/v14061189","article-title":"Kinetics in HBsAg after stopping entecavir or tenofovir in patients with virological relapse but not clinical relapse","volume":"14","author":"Tseng","year":"2022","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.micpath.2024.106821_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000098","article-title":"Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN","volume":"7","author":"Islam","year":"2023","journal-title":"Hepatol Commun"},{"issue":"10","key":"10.1016\/j.micpath.2024.106821_bib11","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.micpath.2024.106821_bib12","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.micpath.2024.106821_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.micpath.2024.106821_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12929-021-00716-8","article-title":"When human guanylate-binding proteins meet viral infections","volume":"28","author":"Zhang","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.micpath.2024.106821_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.594063","article-title":"Guanylate-binding proteins are critical for effective control of francisella tularensis strains in a mouse Co-culture system of adaptive immunity","volume":"10","author":"Mohammadi","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2024.106821_bib18","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1038\/s41467-022-32127-0","article-title":"Pathogen-selective killing by guanylate-binding proteins as a molecular mechanism leading to inflammasome signaling","volume":"13","author":"Feng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.micpath.2024.106821_bib19","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.3389\/fimmu.2019.03139","article-title":"Guanylate-binding protein 1: an emerging target in inflammation and cancer","volume":"10","author":"Honkala","year":"2019","journal-title":"Front. Immunol."},{"issue":"6769","key":"10.1016\/j.micpath.2024.106821_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/35000617","article-title":"Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins","volume":"403","author":"Prakash","year":"2000","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.micpath.2024.106821_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/imcb.12627","article-title":"Mouse guanylate-binding protein 1 does not mediate antiviral activity against influenza virus in vitro or in vivo","volume":"101","author":"Tessema","year":"2023","journal-title":"Immunol. Cell Biol."},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.23195","article-title":"Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein","volume":"50","author":"Itsui","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.micpath.2024.106821_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.freeradbiomed.2022.11.037","article-title":"Differential expression of interferon inducible protein: guanylate binding protein (GTPASE & GBP2) in severe dengue","volume":"194","author":"Mariappan","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.micpath.2024.106821_bib24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1096\/fj.11-189886","article-title":"A new splice variant of the human guanylate-binding protein 3 mediates anti-influenza activity through inhibition of viral transcription and replication","volume":"26","author":"Nordmann","year":"2012","journal-title":"Faseb. J."},{"issue":"7","key":"10.1016\/j.micpath.2024.106821_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01564-20","article-title":"Identification of the interferon-inducible GTPase GTPASE as major restriction factor for the Hepatitis E virus","volume":"95","author":"Glitscher","year":"2021","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.micpath.2024.106821_bib26","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1128\/JVI.02718-15","article-title":"Guanylate-binding protein 1, an interferon-induced GTPase, exerts an antiviral activity against classical swine fever virus depending on its GTPase activity","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.micpath.2024.106821_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100926","article-title":"Human GTPASE is a microbe-specific gatekeeper of macrophage apoptosis and pyroptosis","volume":"38","author":"Fisch","year":"2019","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.micpath.2024.106821_bib28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Lebosse","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.micpath.2024.106821_bib30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1743-422X-9-292","article-title":"Guanylate-binding protein 1 participates in cellular antiviral response to dengue virus","volume":"9","author":"Pan","year":"2012","journal-title":"Virol. J."},{"issue":"7","key":"10.1016\/j.micpath.2024.106821_bib31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jfma.2017.12.007","article-title":"Phase IV randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B","volume":"117","author":"Hsu","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"issue":"5","key":"10.1016\/j.micpath.2024.106821_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.micpath.2024.106821_bib33","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.4049\/jimmunol.0903116","article-title":"Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine","volume":"184","author":"Mirpuri","year":"2010","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.micpath.2024.106821_bib35","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1111\/febs.15611","article-title":"Stimulation of GMP formation in hGTPASE is mediated by W79 and its effect on the antiviral activity","volume":"288","author":"Raninga","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.micpath.2024.106821_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105584","article-title":"miR-548c-3p targets TRIM22 to attenuate the Peg-IFN-alpha therapeutic efficacy in HBeAg-positive patients with chronic hepatitis B","volume":"213","author":"Lin","year":"2023","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.micpath.2024.106821_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/viro.1999.9614","article-title":"Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus","volume":"256","author":"Anderson","year":"1999","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.micpath.2024.106821_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02054-21","article-title":"Guanylate-binding protein-dependent noncanonical inflammasome activation prevents burkholderia thailandensis-induced multinucleated giant cell formation","volume":"12","author":"Dilucca","year":"2021","journal-title":"mBio"},{"issue":"7680","key":"10.1016\/j.micpath.2024.106821_bib39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature24467","article-title":"Ubiquitination and degradation of GBPs by a Shigella effector to suppress host defence","volume":"551","author":"Li","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.micpath.2024.106821_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0065-3527(07)70006-4","article-title":"Viral stress-inducible genes","volume":"70","author":"Sen","year":"2007","journal-title":"Adv. Virus Res."},{"issue":"7344","key":"10.1016\/j.micpath.2024.106821_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature09907","article-title":"A diverse range of gene products are effectors of the type I interferon antiviral response","volume":"472","author":"Schoggins","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib42","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2018.01.034","article-title":"Hepatitis B virus does not interfere with innate immune responses in the human liver","volume":"154","author":"Suslov","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib43","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1053\/j.gastro.2018.01.044","article-title":"HBV bypasses the innate immune response and does not protect HCV from antiviral activity of interferon","volume":"154","author":"Mutz","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.micpath.2024.106821_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: is there still a role for interferon?","volume":"38","author":"Vigano","year":"2018","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.micpath.2024.106821_bib34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-011-9280-0","article-title":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients","volume":"7","author":"Piratvisuth","year":"2013","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.micpath.2024.106821_bib45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.micpath.2024.106821_bib46","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1128\/JVI.00621-06","article-title":"Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity","volume":"80","author":"Blanchet","year":"2006","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.micpath.2024.106821_bib47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","author":"Block","year":"2007","journal-title":"Clin. Liver Dis."},{"issue":"3","key":"10.1016\/j.micpath.2024.106821_bib48","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1073\/pnas.88.3.1059","article-title":"The role of envelope proteins in hepatitis B virus assembly","volume":"88","author":"Bruss","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl 4","key":"10.1016\/j.micpath.2024.106821_bib49","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/0168-8278(91)90036-B","article-title":"Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein","volume":"13","author":"Fernholz","year":"1991","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.micpath.2024.106821_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216028120","article-title":"LPS-aggregating proteins GTPASE and GBP2 are each sufficient to enhance caspase-4 activation both in cellulo and in vitro","volume":"120","author":"Dickinson","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.micpath.2024.106821_bib51","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1038\/s41467-020-16889-z","article-title":"Human GTPASE binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria","volume":"11","author":"Santos","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024002882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401024002882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:28:33Z","timestamp":1724970513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401024002882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":50,"alternative-id":["S0882401024002882"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2024.106821","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the role of GTPase in inhibiting HBV replication and enhancing interferon therapy efficacy in chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2024.106821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106821"}}